首页> 美国卫生研究院文献>Scientia Pharmaceutica >A Competent and Commercially Viable Process for the Synthesis of the Anti-Hypertensive Drug Olmesartan Medoxomil
【2h】

A Competent and Commercially Viable Process for the Synthesis of the Anti-Hypertensive Drug Olmesartan Medoxomil

机译:合成抗高血压药物奥美沙坦Medoxomil的有效商业方法

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Drug product purity and potency are of most significance in the regulatory market as we notice many recalled batches worldwide, particularly in the US and Japan. Olmesartan Medoxomil is an anti-hypertensive drug. The present invention relates to a process for the preparation of Olmesartan Medoxomil with 99.9% purity in an overall 62% yield. The synthesis includes three isolations and one purification with easy plant operations. This process describes the formation and control of each individual impurity in all stages. This process for Olmesartan Medoxomil and its intermediates is competent for industrial production in very short reaction time intervals with an appreciable yield and high purity.
机译:药品的纯度和效力在监管市场中最为重要,因为我们注意到全球有许多召回批次,尤其是在美国和日本。 Olmesartan Medoxomil是一种抗高血压药。本发明涉及一种纯度为99.9%,总产率为62%的奥美沙坦美多西米的制备方法。该合成包括三种分离和一种纯化,且易于工厂操作。此过程描述了所有阶段中每种杂质的形成和控制。 Olmesartan Medoxomil及其中间体的这一方法可在非常短的反应时间间隔内以可观的收率和高纯度用于工业生产。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号